Key Points
- CEO Christopher Peetz sold 30,000 Mirum Pharmaceuticals shares at an average price of $98.68, generating approximately $2.96 million. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, leaving him with 194,440 shares.
- Mirum reported quarterly revenue of $176.24 million, up 37.9% year over year and above analyst estimates, but its adjusted loss of $1.06 per share was wider than expected.
- Analysts remain broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $137.31, well above the stock’s reported $100.63 opening price.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 658 shares of the business's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $100.00, for a total transaction of $65,800.00. Following the transaction, the senior vice president directly owned 616 shares in the company, valued at approximately $61,600. The trade was a 51.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jolanda Howe also recently made the following trade(s):
- On Tuesday, August 18th, Jolanda Howe sold 40,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $100.00, for a total transaction of $4,000,000.00.
- On Monday, August 3rd, Jolanda Howe sold 1,840 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $105.29, for a total transaction of $193,733.60.
- On Wednesday, July 1st, Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $120.00, for a total transaction of $326,520.00.
- On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $101.95, for a total transaction of $264,458.30.
Mirum Pharmaceuticals Stock Performance
NASDAQ:MIRM opened at $100.63 on Friday. The company's 50-day moving average is $109.55 and its two-hundred day moving average is $101.74. Mirum Pharmaceuticals, Inc. has a 1-year low of $63.23 and a 1-year high of $130.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74. The firm has a market capitalization of $6.53 billion, a price-to-earnings ratio of -6.92 and a beta of 0.49.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.32). The firm had revenue of $176.24 million for the quarter, compared to analyst estimates of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The firm's quarterly revenue was up 37.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.12) EPS. Analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current year.
Wall Street Analyst Weigh In
Several equities research analysts have issued reports on the company. UBS Group set a $137.00 target price on Mirum Pharmaceuticals in a research note on Thursday, August 27th. Royal Bank Of Canada decreased their price target on Mirum Pharmaceuticals from $148.00 to $135.00 and set an "outperform" rating on the stock in a research note on Thursday, August 6th. Robert W. Baird set a $123.00 price target on Mirum Pharmaceuticals in a report on Thursday, August 6th. HC Wainwright cut their price objective on Mirum Pharmaceuticals from $185.00 to $140.00 and set a "buy" rating for the company in a research report on Thursday, August 6th. Finally, Wolfe Research began coverage on shares of Mirum Pharmaceuticals in a report on Tuesday, May 19th. They issued an "outperform" rating and a $145.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $137.31.
Check Out Our Latest Research Report on Mirum Pharmaceuticals
Hedge Funds Weigh In On Mirum Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of MIRM. Jupiter Topco LLC acquired a new stake in shares of Mirum Pharmaceuticals during the second quarter worth about $691,672,000. California State Teachers Retirement System grew its holdings in shares of Mirum Pharmaceuticals by 12,542.7% in the second quarter. California State Teachers Retirement System now owns 5,622,989 shares of the company's stock valued at $658,283,000 after purchasing an additional 5,578,513 shares in the last quarter. BlackRock Inc. purchased a new stake in Mirum Pharmaceuticals during the 2nd quarter worth approximately $513,945,000. William Blair Investment Management LLC purchased a new stake in Mirum Pharmaceuticals during the 2nd quarter worth approximately $164,453,000. Finally, Janus Henderson Group PLC increased its stake in Mirum Pharmaceuticals by 21.4% during the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company's stock worth $479,050,000 after buying an additional 1,067,722 shares during the period.
Mirum Pharmaceuticals Company Profile
(
Get Free Report)
Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.
Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
